Senti Bio Announces Second Quarter 2024 Results and Reviews Recent Corporate and Pipeline Highlights
August 13, 2024 16:05 ET
|
Senti Biosciences, Inc.
– Dose finding ongoing in Phase 1 clinical trial of SENTI-202 for the treatment of relapsed/refractory hematologic malignancies including AML – – Commencement of $8 million grant award from CIRM...
Hepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b ‘ASCEND-NASH’ Trial
April 19, 2024 16:30 ET
|
Hepion Pharmaceuticals, Inc.
EDISON, N.J., April 19, 2024 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company that has been developing a treatment for non-alcoholic...
[Latest] Global Liver Cancer Market Size/Share Worth USD 16.3 Billion by 2033 at a 14.5% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
April 03, 2024 12:30 ET
|
Custom Market Insights
Austin, TX, USA, April 03, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Liver Cancer Market Size, Trends and Insights By Type (Hepatocellular Carcinoma...
Hepion Pharmaceuticals Announces Exercise of Warrants for Approximately $2.0 Million Aggregate Gross Proceeds
February 16, 2024 08:00 ET
|
Hepion Pharmaceuticals, Inc.
EDISON, N.J., Feb. 16, 2024 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on artificial intelligence assisted therapeutic drug...
Elevar Therapeutics to Present at Cantor Fitzgerald Global Healthcare Conference
September 21, 2023 09:00 ET
|
Elevar Therapeutics
FORT LEE, N.J., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating...
Elevar Therapeutics Joins Benefactors Council of Blue Faery, Leading Hepatocellular Carcinoma Advocacy Group
September 19, 2023 09:00 ET
|
Elevar Therapeutics
FORT LEE, N.J., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating...
The Importance of Accurate Coding and Documentation in Value-Based Care
July 25, 2023 09:00 ET
|
CHESS Health Solutions
Winston-Salem, NC, July 25, 2023 (GLOBE NEWSWIRE) -- Much has been written about the gaming of risk coding to drive additional revenue, particularly in the Medicare Advantage (MA) program. From a...
Elevar Therapeutics to Participate in ASCO 2023 and BIO 2023; New Jersey-based Company Secures State License as It Builds Toward Commercialization
June 01, 2023 08:00 ET
|
Elevar Therapeutics
FORT LEE, N.J., June 01, 2023 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating...
Elevar Therapeutics to Present Clinically Supported Poster at AACR 2023 Demonstrating Rivoceranib as a Potent, and Most Selective, TKI for VEGFR-2
March 16, 2023 08:00 ET
|
Elevar Therapeutics
FORT LEE, N.J., March 16, 2023 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for patients who...
Advanced Liver Cancer Drug Pipeline Prospers with an Inrush of Pharma Companies and Emerging Novel Therapies
April 29, 2021 20:30 ET
|
DelveInsight Business Research LLP
Los Angeles, USA, April 29, 2021 (GLOBE NEWSWIRE) -- Advanced Liver Cancer Drug Pipeline Prospers with an Inrush of Pharma Companies and Emerging Novel Therapies A comprehensive analysis of...